Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Third Quarter & Nine-Months Ended ...
July 30 2015 - 4:30PM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its fiscal third quarter and
nine-months ended June 30, 2015 financial results after the U.S.
markets close on August 6, 2015. Enanta management will host a
conference call at 4:30 p.m. ET to discuss these results and
Enanta’s business.
Conference Call and Webcast InformationTo participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 6:30
p.m. Eastern time on August 6, 2015, through 11:59 p.m. Eastern
time on August 12, 2015 by dialing (855) 859-2056 from the U.S. or
(404) 537-3406 for international callers. The passcode for both the
live call and the replay is 82580357. A live audio webcast of the
call and replay can be accessed by visiting the “Calendar of
Events” section on the “Investors” page of Enanta’s website at
www.enanta.com.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta is discovering, and in some cases developing, novel
inhibitors designed for use against the hepatitis C virus (HCV).
These inhibitors include members of the direct acting antiviral
(DAA) inhibitor classes – protease (partnered with AbbVie), NS5A,
and nucleotide polymerase – as well as a host-targeted antiviral
(HTA) inhibitor class targeted against cyclophilin. Enanta’s lead
protease inhibitor, paritaprevir, is part of AbbVie’s recently
approved HCV treatment regimens. In addition, Enanta has a
preclinical program in non-alcoholic steatohepatitis, or NASH,
which is a condition that results in liver inflammation and damage
caused by a buildup of fat in the liver.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150730006425/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024